Drug Trial Radar · NCT07712588
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
880
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Jan 2031
Study completion Feb 2032
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP.
Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
BirelentinibDrug
Specified dose on specified days
RituximabDrug
Specified dose on specified days
CyclophosphamidDrug
Specified dose on specified days
DoxorubicinDrug
Specified dose on specified days
VincristineDrug
Specified dose on specified days
PrednisoneDrug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence and severity of adverse eventsTime frame: Up to 2 years
- Part B: Progression-free survival (PFS)Time frame: Up to 5 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Hunan Cancer Hospital
Changsha, Hunan, China
Cancer Hospital of Shandong Frist Medical University
Jinan, Shangdong, China
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.